Summary Comments
- Most frequently detected viruses across all age groups during April 2024:
- Rhinovirus: 21.1%
- Influenza A: 20.6%
- RSV: 18.9%
- Epidemiological Week 1–18:
- SARS-CoV-2: Stable over the last 5 weeks
- Influenza A: Sharp rise from week 15; peaked at 34.9% in week 18
- RSV: Declined to 13.1% in week 18
- Subtype: Majority of influenza A cases were identified as H1N1 2009
Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR: All Age Groups
March 2024:
- Rhino/Enterovirus: 25.3%
- Rhinovirus: 21.0%
- RSV: 21.0%
- SARS-CoV-2: 9.2%
- Influenza A: 7.9%
- Influenza B: 3.3%
- Metapneumovirus: 4.7%
- Adenovirus: 5.2%
- Parainfluenza 1–4: 1.8%
- Coronavirus (non-SARS-CoV-2): 6.3%
April 2024:
- Rhino/Enterovirus: 21.1%
- Rhinovirus: 21.1%
- RSV: 18.9%
- SARS-CoV-2: 8.68%
- Influenza A: 20.6%
- Influenza B: 3.3%
- Metapneumovirus: 6.1%
- Adenovirus: 5.6%
- Parainfluenza 1–4: 0.5%
- Coronavirus (non-SARS-CoV-2): 6.3%
Weekly % Positivity (Weeks 1–18)
- SARS-CoV-2: Stable
- Influenza A: Climbed steadily from week 15, peaking at 34.9% in week 18
- RSV: Declined to 13.1% by week 18
Atypical Bacterial Pathogens (Weeks 1–18)
Cases per Pathogen:
- B. pertussis
- M. pneumoniae
- C. pneumoniae
Notable:
- 3 cases of Legionella pneumophila pneumonia were detected in April
Age Distribution:
Bordetella pertussis:
- 0–6 months: 17%
- 6–12 months: 8%
- 1–5 years: 31%
- 6–12 years: 17%
- 13–18 years: 1%
- 19–64 years: 18%
65 years: 8%
Mycoplasma pneumoniae:
- 0–6 months: 2%
- 6–12 months: 7%
- 1–5 years: 26%
- 6–12 years: 28%
- 13–18 years: 9%
- 19–64 years: 24%
65 years: 4%
Chlamydia pneumoniae:
- 0–6 months: 1%
- 6–12 months: 2%
- 1–5 years: 47%
- 6–12 years: 35%
- 13–18 years: 2%
- 19–64 years: 12%
65 years: 1%
Weekly Case Totals:
B. pertussis:
5, 9, 7, 6, 9, 9, 5, 6, 4, 4, 1, 3, 1, 0, 0, 4, 1, 3
M. pneumoniae:
5, 15, 13, 23, 10, 11, 15, 20, 14, 13, 17, 14, 6, 12, 10, 12, 16, 12
C. pneumoniae:
5, 7, 10, 8, 18, 12, 15, 22, 7, 15, 18, 30, 17, 20, 15, 21, 30, 26
Paediatric Respiratory Viral Multiplex PCR Data (Ages 0–12)
<1 Year Age Group
March 2024:
- RSV: 30.1%
- Rhino/Enterovirus: 27.7%
- Rhinovirus: 39.1%
- Metapneumovirus: 7.5%
- Parainfluenza 1–4: 5.7%
- Adenovirus: 4.7%
- SARS-CoV-2: 9.0%
- Influenza A: 1.9%
- Influenza B: 0.8%
April 2024:
- RSV: 47%
- Rhino/Enterovirus: 27.7%
- Rhinovirus: 39.1%
- Metapneumovirus: 5.9%
- Parainfluenza 1–4: 3.4%
- Adenovirus: 4.5%
- SARS-CoV-2: 9.1%
- Influenza A: 0.8%
- Influenza B: 0.3%
1–5 Year Age Group
March 2024:
- RSV: 35.2%
- Rhino/Enterovirus: 32.3%
- Rhinovirus: 30.8%
- Metapneumovirus: 6.1%
- Parainfluenza 1–4: 9.1%
- Adenovirus: 6.3%
- SARS-CoV-2: 14.3%
- Influenza A: 4.2%
- Influenza B: 2.6%
April 2024:
- RSV: 30.8%
- Rhino/Enterovirus: 32.3%
- Rhinovirus: 30.8%
- Metapneumovirus: 2.5%
- Parainfluenza 1–4: 6.3%
- Adenovirus: 3.6%
- SARS-CoV-2: 13.8%
- Influenza A: 22.1%
- Influenza B: 0.7%
6–12 Year Age Group
March 2024:
- RSV: 7.4%
- Rhino/Enterovirus: 26.0%
- Rhinovirus: 7.3%
- Influenza A: 5.6%
- SARS-CoV-2: 5.1%
- Metapneumovirus: 5.4%
- Parainfluenza 1–4: 3.9%
- Adenovirus: 3.4%
- Influenza B: 0.9%
April 2024:
- RSV: 1.6%
- Rhino/Enterovirus: 26.0%
- Rhinovirus: 7.3%
- Influenza A: 23.4%
- SARS-CoV-2: 3.6%
- Metapneumovirus: 3.4%
- Parainfluenza 1–4: 3.8%
- Adenovirus: 0.5%
- Influenza B: 0.3%
Continue Reading